Within the TME, high LILRB4 expression on tumor-infiltrating immune cells predicted increased risk of postoperative recurrence, shorter OS, and reduced RFS, establishing it as an independent prognostic factor 330. The gene discussed is LILRB4; the disease is neoplasm.